Showing results (151-160 of 245) with videos related to
Sort By:
Pageof 25
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemiaAksinija A Kogan, Michael J Topper, Anna J Dellomo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myelomaAshraf Badros, Angelika M Burger, Sunita Philip, et al.JCO Oncology Practice|April 14, 2023
Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance TrialsVijaya Raj Bhatt, Angela M Ulrich, Geoffrey L Uy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylationMeir Wetzler, Michael T Brady, Erin Tracy, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 17, 2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemiaKyle Zacholski, Bryan Hambley, Erin Hickey, et al.Blood|December 9, 2024
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesJacqueline S Garcia, Uwe Platzbecker, Olatoyosi Odenike, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Michael A Caligiuri, et al.Oncotarget|September 10, 2021
Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplicationMario Scarpa, Shivani Kapoor, Eric S Tvedte, et al.Leukemia Research|March 5, 2024
Clinical outcomes of patients with acute myeloid leukemia and cardiovascular diseaseGabriela Sanchez-Petitto, Olga G Goloubeva, Jack Masur, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic TransplantationKeith W Pratz, Michelle A Rudek, B Douglas Smith, et al.Pageof 25